This 2010 study investigated the effects of ezlopitant, a selective neurokinin 1 (NK1) receptor antagonist, on the consumption and motivation for sucrose and ethanol in rodent models. Ezlopitant significantly reduced operant self-administration of 5% sucrose in a dose-dependent manner, with all tested doses (2, 5, and 10 mg/kg) decreasing intake.
